LINTZERIS CASE SERIES
The case series investigated the effectiveness of PuraPly® AM in refractory wounds of various etiologies.1
Retrospective case series to assess ability of PuraPly AM to control biofilm formation, sequester proteolytic enzymes, and provide a biocompatible scaffold to support healing for patients with multiple comorbidities who did not respond to previous conventional or adjuvant therapy.
- A single-center, retrospective case series
- PuraPly AM was applied once weekly after debridement wherever applicable after the wound bed was sharply debrided
- The PuraPly AM was moistened with saline to improve handling characteristics and conformity to the surface of the wound and secured in place with adhesive strips. The product was then covered with a nonadherent primary dressing (ADAPTIC TOUCH Non-Adhering Silicone Dressing; Acelity, San Antonio, TX) and moisture-retentive secondary dressings (AQUACEL; ConvaTec, Bridgewater, NJ) as required
- Compression therapy and/or offloading was administered as appropriate
- Wounds were assessed weekly and good conventional care was administered concurrently throughout the course of treatment
- A total of 9 wounds on 8 patients
- The age of the patients ranged from 52-79 years old
- All the patients had significant comorbidities
- The average wound size at the first PuraPly AM application was 34 cm2
- The average wound duration prior to PuraPly AM application was 9.2 weeks
Average number of PuraPly AM applications
6 wounds healed and 3 had an average area reduction of 61.4% with 100% granulation
Average time to closure for the 6 healed wounds
Please refer to the PuraPly AM Instructions for Use for complete prescribing information.
- Lintzeris D, et al. Wounds. 2018;30(3):72-78.